BTIG analyst Julian Harrison raised the firm’s price target on Spyre Therapeutics to $40 from $32 and keeps a Buy rating on the shares after its Q1 results. The firm is reducing its assumed discount rate to 15% from 17.5%, citing the company’s broad platform derisking and fortified cash runway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Carvana upgraded, Block downgraded: Wall Street’s top analyst calls
- Spyre Therapeutics initiated with an Outperform at Baird
- Spyre Therapeutics files to sell 33.36M shares of common stock for holders
- Spyre Therapeutics price target raised to $54 from $36 at Stifel